Drug Search Results
More Filters [+]

TRU-015

Alternative Names: tru-015, tru015, tru 015
Latest Update: 2021-02-18
Latest Update Note: Clinical Trial Update

Product Description

TRU-015, being developed by Trubion Pharmaceuticals Inc and Pfizer Inc, is an intravenously administered anti-CD20 IgG fusion protein for the treatment of rheumatoid arthritis. TRU-015 depletes B-cells from the peripheral blood in vitro, and can mediate complement-and antibody-dependent cellular cytotoxicity. TRU-015 was well tolerated in patients with rheumatoid arthritis in phase I and II clinical trials, and demonstrated an efficacy profile similar to other biological agents approved for rheumatoid arthritis. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/20140823/)

Mechanisms of Action: CD20 Antagonist

Novel Mechanism: No

Modality: Fusion Protein

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Pfizer
Company Location: NEW YORK NY 10017
Company CEO: Albert Bourla
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for TRU-015

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Arthritis, Rheumatoid|Lymphoma, B-Cell

Phase 1: Lymphoma, Non-Hodgkin|Lymphoma, B-Cell|Glomerulonephritis, Membranous|Lupus Nephritis|Lupus Erythematosus, Systemic|Kidney Diseases

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

2007-006150-25

P2

Completed

Arthritis, Rheumatoid

2010-06-28

3206K1-2203

P2

Terminated

Arthritis, Rheumatoid

2010-02-01

3206K3-103

P1

Terminated

Lupus Nephritis|Lupus Erythematosus, Systemic|Glomerulonephritis, Membranous|Kidney Diseases

2008-05-01

3206K2-104

P1

Terminated

Lymphoma, Non-Hodgkin|Lymphoma, B-Cell

2008-04-01

42%

Recent News Events

Date

Type

Title